Clinical Trials Data Analysis Hepatic Encephalopathy

Natural History of Patients Taking Rifaximin-α for Recurrent Hepatic Encephalopathy and Risk of Future Overt Episodes and Mortality: A Post-hoc Analysis of Clinical Trials Data

Bannister Ch A, Orr J G, Reynolds A V, Hudson M, Conway P, Radwan A, Morgan C L, Currie C J. 29 Apr 2016

HCRU Hepatic Encephalopathy

The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin-α

Orr J G, Currie C J, Berni E R, Goel A, Moriarty K J, Sinha A, Gordon F, Dethier A, Dillon J F, Clark K, Richardson P, Middleton P, Patel V, Shawcross D, Preedy H, Aspinall R J, Hudson M. 07 Mar 2016

We use cookies to give you the best online experience. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services